{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:30:54Z","timestamp":1767375054954},"reference-count":45,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The approval of brentuximab vedotin (BV) and the PD-1 inhibitors nivolumab and pembrolizumab has dramatically improved outcomes for patients with relapsed or refractory (R\/R) classic Hodgkin lymphoma (HL). With the goal of increasing long-term disease control rates and decreasing late toxicities, these agents are currently being tested in earlier phases of treatment in combination with chemotherapy agents. In the R\/R setting, our expanding understanding of HL\u2019s various mechanisms of immune evasion and treatment resistance has spurred a growing number of rationally designed combination trials. Beyond BV and PD-1 blockade, other novel therapies have demonstrated encouraging preliminary results, including targeted agents, like the CD25 antibody-drug conjugate ADCT-301, and cellular therapies, including CD30 chimeric antigen receptor T cells and Epstein-Barr virus (EBV)-directed cytotoxic T cells. These trials, coupled with the rapid development of prognostic and predictive biomarkers, should drive additional breakthroughs that promise safer and more effective therapies for patients with HL in the future.<\/jats:p>","DOI":"10.1182\/hematology.2019000029","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T10:12:10Z","timestamp":1575627130000},"page":"243-248","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Novel agents and immune invasion in Hodgkin lymphoma"],"prefix":"10.1182","volume":"2019","author":[{"given":"Reid W.","family":"Merryman","sequence":"first","affiliation":[{"name":"Department of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"LaCasce","sequence":"additional","affiliation":[{"name":"Department of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"23","key":"2019120610095703500_B1","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.91.23.10962","article-title":"Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development","volume":"91","author":"K\u00fcppers","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"issue":"18","key":"2019120610095703500_B2","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"14","key":"2019120610095703500_B3","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2010.32.8401","article-title":"Molecular pathogenesis of Hodgkin\u2019s lymphoma: increasing evidence of the importance of the microenvironment","volume":"29","author":"Steidl","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019120610095703500_B4","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical Hodgkin lymphoma with reduced \u03b22M\/MHC class i expression is associated with inferior outcome independent of 9p24.1 status","volume":"4","author":"Roemer","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"23","key":"2019120610095703500_B5","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019120610095703500_B6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41408-019-0185-9","article-title":"Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma","volume":"9","author":"Jalali","year":"2019","journal-title":"Blood Cancer J"},{"issue":"4","key":"2019120610095703500_B7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"31","key":"2019120610095703500_B8","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"issue":"14","key":"2019120610095703500_B9","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019120610095703500_B10","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"2019120610095703500_B11","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1002\/hon.2437_54","article-title":"Blockade of the PD-1 checkpoint with anti-PD-L1 antibody avelumab is sufficient for clinical activity in relapsed\/refractory classical Hodgkin lymphoma (CHL)","volume":"35","author":"Chen","year":"2017","journal-title":"Hematol Oncol"},{"issue":"25","key":"2019120610095703500_B12","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided byinterim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"2019120610095703500_B13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"8852","key":"2019120610095703500_B14","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"issue":"9323","key":"2019120610095703500_B15","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"issue":"15","key":"2019120610095703500_B16","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2017-09-772673","article-title":"Transplant strategies in relapsed\/refractory Hodgkin lymphoma","volume":"131","author":"Shah","year":"2018","journal-title":"Blood"},{"issue":"23","key":"2019120610095703500_B17","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","article-title":"Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"116","author":"Moskowitz","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019120610095703500_B18","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"2019120610095703500_B19","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/annonc\/mdx791","article-title":"Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"29","author":"Herrera","year":"2018","journal-title":"Ann Oncol"},{"issue":"1","key":"2019120610095703500_B20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2019120610095703500_B21","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/annonc\/mdz009","article-title":"Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)","volume":"30","author":"Garcia-Sanz","year":"2019","journal-title":"Ann. Oncol"},{"issue":"11","key":"2019120610095703500_B22","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1093\/annonc\/mdq211","article-title":"Serious pulmonary toxicity in patients with Hodgkin\u2019s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an Fc\u03b3RIIIa-158 V\/F polymorphism","volume":"21","author":"Blum","year":"2010","journal-title":"Ann Oncol"},{"issue":"11","key":"2019120610095703500_B23","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"issue":"9980","key":"2019120610095703500_B24","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"2019120610095703500_B25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.2019000215","article-title":"PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation","volume":"134","author":"Armand","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2019120610095703500_B26","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.2009.07727.x","article-title":"Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma","volume":"146","author":"Moskowitz","year":"2009","journal-title":"Br J Haematol"},{"issue":"12","key":"2019120610095703500_B27","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2019120610095703500_B28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/blood.V128.22.183.183","article-title":"A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039)","volume":"128","author":"Ansell","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"2019120610095703500_B29","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2018-99-115390","article-title":"A phase I study with an expansion cohort of the combinations of ipilimumab, nivolumab and brentuximab vedotin in patients with relapsed\/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN Research Group (E4412: Arms G-I)","volume":"132","author":"Diefenbach","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2019120610095703500_B30","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1182\/blood-2018-99-118506","article-title":"A phase 1b study investigating the combination of the tetravalent bispecific NK cell engager AFM13 and pembrolizumab in patients with relapsed\/refractory Hodgkin lymphoma after brentuximab vedotin failure: updated safety and efficacy data","volume":"132","author":"Bartlett","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2019120610095703500_B31","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1182\/blood-2018-99-118198","article-title":"Phase 1 study of Adct-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed\/refractory classical Hodgkin lymphoma","volume":"132","author":"Hamadani","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2019120610095703500_B32","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3324\/haematol.2017.180554","article-title":"A phase II study of the oral JAK1\/JAK2 inhibitor ruxolitinib in advanced relapsed\/refractory Hodgkin lymphoma","volume":"103","author":"Van Den Neste","year":"2018","journal-title":"Haematologica"},{"issue":"33","key":"2019120610095703500_B33","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1200\/JCO.2012.42.5223","article-title":"Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019120610095703500_B34","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1182\/blood-2011-07-362475","article-title":"A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma","volume":"118","author":"Fehniger","year":"2011","journal-title":"Blood"},{"issue":"18","key":"2019120610095703500_B35","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2011.38.1350","article-title":"Panobinostat in patients with relapsed\/refractory Hodgkin\u2019s lymphoma after autologous stem-cell transplantation: results of a phase II study","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019120610095703500_B36","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/annonc\/mdx028","article-title":"Phase II study of idelalisib, a selective inhibitor of PI3K\u03b4, for relapsed\/refractory classical Hodgkin lymphoma","volume":"28","author":"Gopal","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"2019120610095703500_B37","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40164-018-0103-z","article-title":"Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma","volume":"7","author":"Johnston","year":"2018","journal-title":"Exp Hematol Oncol"},{"issue":"suppl 1","key":"2019120610095703500_B38","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2018-99-111202","article-title":"CD30-chimeric antigen receptor (CAR) T cells for therapy of hodgkin lymphoma (HL)","volume":"132","author":"Ramos","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2019120610095703500_B39","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019120610095703500_B40","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.2017.74.3179","article-title":"Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed Hodgkin lymphoma","volume":"36","author":"Bollard","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019120610095703500_B41","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/bmt.2015.332","article-title":"Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis","volume":"51","author":"Rashidi","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2019120610095703500_B42","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2019120610095703500_B43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2018-02-811174","article-title":"Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil","volume":"132","author":"Herbaux","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2019120610095703500_B44","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/ajh.25154","article-title":"Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers","volume":"93","author":"Rossi","year":"2018","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2019120610095703500_B45","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1182\/blood-2018-99-117672","article-title":"Checkpoint blockade therapy may sensitize Hodgkin lymphoma to subsequent therapy","volume":"132","author":"Carreau","year":"2018","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2019\/1\/243\/1545989\/hem2019000029c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2019\/1\/243\/1545989\/hem2019000029c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T10:12:25Z","timestamp":1575627145000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2019\/1\/243\/422549\/Novel-agents-and-immune-invasion-in-Hodgkin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,6]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2019000029","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,6]]}}}